Episodebeskrivelse
Many investors avoided antimicrobial resistance. Then Eli Lilly agreed to pay up to US$780 million for LimmaTech Biologics, a vaccine developer backed by Tenmile. Dr Steve Burnell explains what a contrarian thesis, pharma's growing appetite for early assets and Australia's funding gap mean for the next wave of biotech.
This is the one episode you want to listen to if you want to know where Biotech is going in 2026 - what matters, where capital is moving, what investors are actually looking for and where Australia fits in all that.
Join us as we deep dive into this $250M funds formation, thesis and operations built with expertise from decades across the US and Aussie health system.
Emily Casey, founder and Director of What the Health, is joined by Dr Steve Burnell, Managing Director of Tenmile, the Tattarang-owned health technology investment business launched with an initial A$250 million allocation.
Dr Burnell is Managing Director of Tenmile and Chair of its Investment Committee. Before Tenmile he managed a global business, led M&A and established a new informatics and real-world data business at Roche-Genentech in the US. He remains a senior strategic advisor to Minderoo Foundation, where he led large initiatives in COVID-19, cancer and ocean genomics. He holds a BSc (Hons) in Biology and a PhD in Population Biology from the University of Sydney.
Together they unpack:
• Where Australia's capital gap really sits: late pre-clinical and early clinical stages, where rounds run to tens of millions
• Why pharma is moving earlier, and what the patent cliff means for dealmaking
• Why Dr Burnell says antimicrobial resistance was a hard sell for investors, and what changed before Lilly's LimmaTech deal
• The "who pays?" test every founder should pass before pitching, with Heidi Health as a case study
• How Tenmile screens by theme, tests the science and the team, then moves through diligence and syndication
• The founder mistakes to avoid, including how to approach NDAs
• Tenmile's investment themes beyond antimicrobials: women's health, mental health, oncology and AI in drug discovery
• Where he expects medicine to head by 2035: personalised mRNA medicines and a deeper understanding of the immune system
Chapters
00:00 Why this conversation, and a path from marine biology to Roche
08:30 What Tenmile is and how the Forrest backing came about
14:20 Australia's valley of death and where the capital gap really sits
19:56 What would fix it: coordinated capital, companies that stay onshore, US investors
26:47 Is biotech overheating? AI, the patent cliff and pharma buying earlier
31:56 The contrarian bet: antimicrobial resistance and the LimmaTech exit
36:09 Why founders must answer "who pays?"
42:15 Where the next breakthroughs are: personalised mRNA, AI and drug discovery
47:33 Tenmile's investment themes and what comes next for Tenmile
54:33 How Tenmile makes an investment, and the founder mistakes to avoid
1:02:20 Healthcare in 2035, and lessons from a…
Website: dayone.fm

